Extrait

1. To evaluate the efficacy of vismodegib plus ruxolitinib compared with ruxolitinib plus placebo in patients with intermediate- or high-risk myelofibrosis (MF), as measured by spleen response rate at Week 24, determined by an Independent Review Committee (IRC) 2. To evaluate the efficacy of vismodegib plus ruxolitinib compared with ruxolitinib plus placebo in patients with intermediate- or high-risk MF, as measured by response rate (complete remission [CR] and partial remission [PR]) at Week 24, determined by an IRC

Critère d'inclusion

• Intermediate- or high-risk myelofibrosis

Liens

• euctr
• ictrp